.Invite to this week’s Chutes & Ladders, our roundup of notable management hirings, firings and retirings all over the industry. Please deliver the good word–
Read moreChinese insulin maker’s GLP-1 tops Ozempic in ph. 2
.Chinese the hormone insulin maker Gan & Lee Pharmaceuticals is wading into the obesity globe with an injectable GLP-1 agonist that beat Novo Nordisk’s Ozempic
Read moreChina- located biotech plans ph. 3 after viewing midstage eye information
.China-based Minghui Drug has actually connected its own thyroid eye health condition treatment to a decline in eye protruding in a little period 1b/2 professional
Read moreCharles Baum consumes Terremoto as chief executive officer
.Charles Baum, M.D., Ph.D., who managed Mirati Therapies’ $ 5.8 billion sale to Bristol Myers Squibb in 2013, is actually taking the command of youthful
Read moreCelldex anti-cKIT antitoxin lessen hives in another stage 2 research
.It’s challenging to muscular tissue in on a room as competitive as immunology, yet Celldex Therapies strongly believes that its own most current stage 2
Read moreCell- concentrated Sana scoops very first CSO– Chutes & Ladders
.Invite to recently’s Chutes & Ladders, our roundup of considerable management hirings, firings and also retirings across the market. Please send out the recommendation– or
Read moreCassava pays for $40M over supposedly deceiving Alzheimer’s upgrade
.Cassava Sciences has actually consented to spend $40 million to solve an inspection right into claims it made deceiving claims concerning period 2b records on
Read moreCash- strapped Gritstone begins look for strategic alternatives as cancer cells injection data underwhelm
.Gritstone bio has actually introduced bankers to explore “prospective value-maximizing approaches” after its own stage 2 colorectal cancer vaccine data fell short of the runaway
Read moreCapricor portions more information for DMD therapy after starting BLA
.Capricor Therapies is actually taking a triumph tour for their phase 2 Duchenne muscle dystrophy (DMD) test. At 3 years, the San Diego-based firm’s cell
Read moreCapricor markets Europe civil liberties to late-stage DMD treatment for $35M
.Having actually scooped up the USA liberties to Capricor Rehabs’ late-stage Duchenne muscular dystrophy (DMD) treatment, Asia’s Nippon Shinyaku has signed off on $35 thousand
Read more